FAQ

SR 49059

Known as: SR-49059, SR49059 
 

Topic mentions per year

Topic mentions per year

1995-2018
0519952018

Related topics

Related topics

1 relation

Broader (1)

relcovaptan

Related mentions per year

Related mentions per year

1995-2018
1990200020102020
SR 49059
relcovaptan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.
The mechanisms by which arginine vasopressin (AVP) exerts its antidiuretic and pressor effects, via activation of V2 and V1a… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
In many mendelian diseases, some mutations result in the synthesis of misfolded proteins that cannot reach a transport-competent… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
Vasopressin inhibits glutamate release via two distinct modes in the brainstem.
The hypothalamus coordinates autonomic responses in part through arginine vasopressin (AVP) released in medial nucleus tractus… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
Vasopressin receptor subtype(s) responsible for stimulation of insulin release from pancreatic beta cells were investigated by… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 3
Is this relevant?
2004
2004
Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.
In most cases, nephrogenic diabetes insipidus results from mutations in the V2 vasopressin receptor (V2R) gene that cause… (More)
Is this relevant?
2004
2004
Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women.
BACKGROUND Compounds that block uterine oxytocin and vasopressin V1a receptors have a therapeutic potential in preterm labor and… (More)
  • table I
  • figure 1
  • figure 2
  • table II
  • table III
Is this relevant?
2003
2003
Vasopressin differentially modulates non-NMDA receptors in vasopressin and oxytocin neurons in the supraoptic nucleus.
Magnocellular neurons of the supraoptic nucleus release the neuropeptides oxytocin and vasopressin from their dendrites to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1999
1999
Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries.
OBJECTIVE The present study was undertaken to examine whether arginine vasopressin (AVP) relaxes primate coronary artery and to… (More)
Is this relevant?
1999
1999
Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study.
A potent non-peptide vasopressin (AVP) antagonist, SR-49059, displaying high stability and selective affinity for the V1a AVP… (More)
Is this relevant?
1995
1995
Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
The effects of SR-49059, a new nonpeptide and selective arginine vasopressin (AVP) V1a antagonist, were investigated in binding… (More)
Is this relevant?